Johnson & Johnson (JNJ) posts promising Phase 2b trial results for its chemotherapy releasing system TAR-200 in bladder ...

Summit Therapeutics' shares dropped 36% after ivonescimab data showed no significant survival benefit. Click to read if SMMT ...

"We have an epidemic right now of feeling like you don't belong," the Michigan U.S. Senate candidate told Newsweek.